Last updated on November 2017

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer


Brief description of study

A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer

Detailed Study Description

The purpose of this research study is to evaluate the effectiveness and safety of one dose of rAd-IFN with Syn3 (InstiladrinTM) given to patients with High Grade BCG-unresponsive non-muscle invasive bladder cancer. Instiladrin™ is a gene transfer agent and is being developed for transfer of the Interferon a-2b gene in into the bladder.

Clinical Study Identifier: TX15170

Contact Investigators or Research Sites near you

Start Over

Candice Fortuna

The Urology Center of Colorado
Denver, CO USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.